Volume 13 Issue 6
Nov.  2022
Turn off MathJax
Article Contents
ZHONG Linqing, SONG Hongmei. Interpretation on the 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 992-998. doi: 10.12290/xhyxzz.2022-0377
Citation: ZHONG Linqing, SONG Hongmei. Interpretation on the 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 992-998. doi: 10.12290/xhyxzz.2022-0377

Interpretation on the 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis

doi: 10.12290/xhyxzz.2022-0377
Funds:

National Key Research and Development Program of China 2021YFC2702003

Natural Science Foundation of Beijing L202050

National High Level Hospital Clinical Research Funding 2022-PUMCH-B-079

More Information
  • Corresponding author: SONG Hongmei, E-mail: songhm1021@hotmail.com
  • Received Date: 2022-07-07
  • Accepted Date: 2022-08-23
  • Available Online: 2022-09-07
  • Publish Date: 2022-11-30
  • In order to improve the prognosis of children with juvenile idiopathic arthritis (JIA), following the treatment guideline issued in 2019, the American College of Rheumatology (ACR) published new guidelines for the treatment of JIA in March 2022, including recommendations for both pharmacologic and nonpharmacologic therapies. The pharmacologic management focuses on treatment of oligoarthritis, temporomandibular joint arthritis, and systemic JIA. This article provides Chinese physicians with detailed interpretation of this guideline, for the purpose of better applying it in their clinical practice.
  • loading
  • [1] Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Syste-mic Juvenile Idiopathic Arthritis[J]. Arthritis Rheumatol, 2022, 74: 553-569. doi:  10.1002/art.42037
    [2] Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging[J]. Arthritis Care Res (Hoboken), 2022, 74: 505-520. doi:  10.1002/acr.24839
    [3] Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis[J]. Arthritis Rheumatol, 2019, 71: 846-863. doi:  10.1002/art.40884
    [4] Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis[J]. Arthritis Rheumatol, 2019, 71: 864-877. doi:  10.1002/art.40885
    [5] Zulian F, Martini G, Gobber D, et al. Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis[J]. Rheumatology (Oxford), 2003, 42: 1254-1259. doi:  10.1093/rheumatology/keg358
    [6] Zulian F, Martini G, Gobber D, et al. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial[J]. Rheumatology (Oxford), 2004, 43: 1288-1291. doi:  10.1093/rheumatology/keh313
    [7] Eberhard BA, Sison MC, Gottlieb BS, et al. Comparison of the intraarticular effectiveness of triamcinolone hexaceto-nide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis[J]. J Rheumatol, 2004, 31: 2507-2512.
    [8] Wallace CA, Huang B, Bandeira M, et al. Patterns of clinical remission in select categories of juvenile idiopathic arthritis[J]. Arthritis Rheum, 2005, 52: 3554-3562. doi:  10.1002/art.21389
    [9] Wallace CA, Giannini EH, Huang B, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis[J]. Arthritis Care Res (Hoboken), 2011, 63: 929-936. doi:  10.1002/acr.20497
    [10] Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis[J]. Arthritis Rheum, 2009, 61: 658-666. doi:  10.1002/art.24516
    [11] McErlane F, Beresford MW, Baildam EM, et al. Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis[J]. Ann Rheum Dis, 2013, 72: 1983-1988. doi:  10.1136/annrheumdis-2012-202031
    [12] Tibaldi J, Pistorio A, Aldera E, et al. Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis[J]. Rheumatology (Oxford), 2020, 59: 3505-3514. doi:  10.1093/rheumatology/keaa240
    [13] Aikawa NE, Trudes G, Campos LM, et al. Immunogeni-city and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients[J]. Lupus, 2013, 22: 1394-1398. doi:  10.1177/0961203313505926
    [14] Toplak N, Subelj V, Kveder T, et al. Safety and efficacy of influenza vaccination in a prospective longitudinal study of 31 children with juvenile idiopathic arthritis[J]. Clin Exp Rheumatol, 2012, 30: 436-444.
    [15] Heijstek MW, Scherpenisse M, Groot N, et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study[J]. Ann Rheum Dis, 2014, 73: 1500-1507. doi:  10.1136/annrheumdis-2013-203429
    [16] Heijstek MW, Kamphuis S, Armbrust W, et al. Effects of the live attenuated measles-mumps-rubella booster vaccina-tion on disease activity in patients with juvenile idiopathic arthritis: a randomized trial[J]. JAMA, 2013, 309: 2449-2456. doi:  10.1001/jama.2013.6768
    [17] Uziel Y, Moshe V, Onozo B, et al. Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: Multicenter, retrospective data collection[J]. Vaccine, 2020, 38: 2198-2201. doi:  10.1016/j.vaccine.2020.01.037
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)

    Article Metrics

    Article views (395) PDF downloads(182) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return